Global Rofecoxib Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rofecoxib Market Research Report 2024
Rofecoxib is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea.Rofecoxib was available by prescription in both tablet-form and as an oral suspension.
According to Mr Accuracy reports’s new survey, global Rofecoxib market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rofecoxib market research.
Key manufacturers engaged in the Rofecoxib industry include Merck, Chengdu Meinkai Chemical Co. LTD, Wuhan Xinxin Jiali Biotechnology Co. LTD, Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD, Pfizer and Tremeau, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Rofecoxib were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Rofecoxib market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rofecoxib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Merck
Chengdu Meinkai Chemical Co. LTD
Wuhan Xinxin Jiali Biotechnology Co. LTD
Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD
Pfizer
Tremeau
Segment by Type
Oral Suspension.
Tablet-Form
Osteoarthritis
Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Acute Pain Conditions
Migraine
Dysmenorrhea
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Rofecoxib report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Rofecoxib market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Rofecoxib market research.
Key manufacturers engaged in the Rofecoxib industry include Merck, Chengdu Meinkai Chemical Co. LTD, Wuhan Xinxin Jiali Biotechnology Co. LTD, Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD, Pfizer and Tremeau, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Rofecoxib were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Rofecoxib market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rofecoxib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
Chengdu Meinkai Chemical Co. LTD
Wuhan Xinxin Jiali Biotechnology Co. LTD
Hubei TuoChu Kang Yuan Pharmaceutical Chemical Co. LTD
Pfizer
Tremeau
Segment by Type
Oral Suspension.
Tablet-Form
Segment by Application
Osteoarthritis
Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Acute Pain Conditions
Migraine
Dysmenorrhea
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Rofecoxib report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source